Showing results (2421-2430 of 6,517) with videos related to
Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|February 6, 2019
Correction to: CD73 expression in normal and pathological human hepatobiliopancreatic tissuesAmedeo Sciarra, Inês Monteiro, Christine Ménétrier-Caux, et al.Cancer Immunology, Immunotherapy : CII|February 6, 2019
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinomaSandra P D'Angelo, Matthias Hunger, Andrew S Brohl, et al.Cancer Immunology, Immunotherapy : CII|February 7, 2019
Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeuticsAnna Felberg, Aleksandra Urban, Anna Borowska, et al.Cancer Immunology, Immunotherapy : CII|January 23, 2019
Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanomaHamzah Abu-Sbeih, Faisal S Ali, Wei Qiao, et al.Cancer Immunology, Immunotherapy : CII|February 14, 2019
Tumor infiltrating mast cells determine oncogenic HIF-2α-conferred immune evasion in clear cell renal cell carcinomaYing Xiong, Li Liu, Yu Xia, et al.Cancer Immunology, Immunotherapy : CII|January 5, 2019
CD73 expression in normal and pathological human hepatobiliopancreatic tissuesAmedeo Sciarra, Inês Monteiro, Christine Ménétrier-Caux, et al.Cancer Immunology, Immunotherapy : CII|December 4, 2018
The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinomaBoyang Chang, Tao Huang, Huajun Wei, et al.Cancer Immunology, Immunotherapy : CII|November 29, 2018
Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymomaSoo Jeong Nam, Young-Hoon Kim, Ji Eun Park, et al.Cancer Immunology, Immunotherapy : CII|January 4, 2020
Lung cancer-derived extracellular vesicles: a possible mediator of mast cell activation in the tumor microenvironmentPazit Salamon, Yoseph A Mekori, Irit SheflerCancer Immunology, Immunotherapy : CII|January 4, 2020
Potential oncogenic roles of mutant-p53-derived exosomes in the tumor-host interaction of head and neck cancersEtti Ester Azulay, Tomer Cooks, Moshe ElkabetsPageof 652